Michael Wiederhorn
Stock Analyst at Oppenheimer
(3.66)
# 798
Out of 5,182 analysts
147
Total ratings
54.86%
Success rate
4.69%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HCA HCA Healthcare | Maintains: Outperform | $540 → $520 | $448.70 | +15.89% | 14 | Apr 27, 2026 | |
| UNH UnitedHealth Group | Maintains: Outperform | $385 → $405 | $356.81 | +13.51% | 19 | Apr 22, 2026 | |
| GRDN Guardian Pharmacy Services | Maintains: Outperform | $35 → $38 | $37.94 | +0.16% | 2 | Mar 12, 2026 | |
| PACS PACS Group | Maintains: Outperform | $40 → $42 | $35.00 | +20.00% | 4 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Outperform | $12 → $7 | $5.80 | +20.69% | 12 | Mar 3, 2026 | |
| EVH Evolent Health | Maintains: Outperform | $12 → $6 | $3.46 | +73.41% | 2 | Mar 2, 2026 | |
| CHE Chemed | Maintains: Outperform | $580 → $500 | - | - | 14 | Feb 27, 2026 | |
| EHAB Enhabit | Upgrades: Outperform | $14 | - | - | 3 | Jan 22, 2026 | |
| CNC Centene | Maintains: Outperform | $51 → $43 | $44.81 | -4.04% | 19 | Jul 28, 2025 | |
| HUM Humana | Maintains: Outperform | $300 → $310 | $224.90 | +37.84% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $375 | $288.46 | +30.00% | 11 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $37 | - | - | 6 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $168 | - | - | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $140 → $145 | - | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4.5 → $5 | $2.85 | +75.44% | 10 | Jul 25, 2024 |
HCA Healthcare
Apr 27, 2026
Maintains: Outperform
Price Target: $540 → $520
Current: $448.70
Upside: +15.89%
UnitedHealth Group
Apr 22, 2026
Maintains: Outperform
Price Target: $385 → $405
Current: $356.81
Upside: +13.51%
Guardian Pharmacy Services
Mar 12, 2026
Maintains: Outperform
Price Target: $35 → $38
Current: $37.94
Upside: +0.16%
PACS Group
Mar 4, 2026
Maintains: Outperform
Price Target: $40 → $42
Current: $35.00
Upside: +20.00%
Teladoc Health
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $7
Current: $5.80
Upside: +20.69%
Evolent Health
Mar 2, 2026
Maintains: Outperform
Price Target: $12 → $6
Current: $3.46
Upside: +73.41%
Chemed
Feb 27, 2026
Maintains: Outperform
Price Target: $580 → $500
Current: -
Upside: -
Enhabit
Jan 22, 2026
Upgrades: Outperform
Price Target: $14
Current: -
Upside: -
Centene
Jul 28, 2025
Maintains: Outperform
Price Target: $51 → $43
Current: $44.81
Upside: -4.04%
Humana
May 1, 2025
Maintains: Outperform
Price Target: $300 → $310
Current: $224.90
Upside: +37.84%
Jan 31, 2025
Maintains: Outperform
Price Target: $400 → $375
Current: $288.46
Upside: +30.00%
Nov 8, 2024
Maintains: Outperform
Price Target: $34 → $37
Current: -
Upside: -
Oct 25, 2024
Maintains: Outperform
Price Target: $165 → $168
Current: -
Upside: -
Sep 23, 2024
Maintains: Outperform
Price Target: $140 → $145
Current: -
Upside: -
Jul 25, 2024
Maintains: Outperform
Price Target: $4.5 → $5
Current: $2.85
Upside: +75.44%